Company Profile

CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors. Its lead candidate Berubicin is for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as pancreatic and ovarian cancers, and lymphonas. The Company entered into an IP agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata Pharmaceuticals Inc.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Pharmaceutical Preparations

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
[email protected]

Company Contact
CNS Pharmaceuticals, Inc.
2100 West Loop South
Suite 900
Houston, TX 77027